ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2452

Early Increase in Urinary Exosomal BK Virus MicroRNA as a Predictive Marker of BK Virus Nephropathy: A Prospective Kidney Transplantation Cohort

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Cho, Won-Hee, Kyung Hee University Hospital at Gangdong Department of Orthopedic Surgery, Seoul, Korea (the Republic of)
  • Jung, Su Woong, Kyung Hee University Hospital at Gangdong Department of Orthopedic Surgery, Seoul, Korea (the Republic of)
  • Moon, Ju young, Kyung Hee University Hospital at Gangdong Department of Orthopedic Surgery, Seoul, Korea (the Republic of)
  • Kim, Yang gyun, Kyung Hee University Hospital at Gangdong, Seoul, Korea (the Republic of)
  • Jeong, Kyung hwan, Kyung Hee University Hospital at Gangdong, Seoul, Korea (the Republic of)
  • Lee, Sangho, Kyung Hee University Hospital at Gangdong, Seoul, Korea (the Republic of)
Background

Urinary exosomal bkv-miR-B1-5p was associated with BK virus (BKV) nephropathy (BKVN) in a cross-sectional study. However, its time-dependent post-transplantation changes and predictive value for BKVN have not been investigated.

Methods

We carried out a multicenter prospective cohort from which 83 kidney transplant recipients (KRTs) in South Korea (biopsy-proven BKVN [n=10], presumptive BKVN [n=12], and non-BKVN patients [n=61]) were selected for the measurement of urinary exosomal bkv-miR-B1-5p levels at 0.5, 3, 6, and 12 months posttransplant.

Results

At 2 weeks posttransplant, urinary exosomal bkv-miR-B1-5p levels showed an increasing trend (non-BKVN < presumptive BKVN < biopsy-proven BKVN), while plasma BKV DNA levels were undetectable in all groups. Thereafter, both urinary exosomal bkv-miR-B1-5p and plasma BKV DNA levels peaked at 3 months posttransplant and then decreased. Multivariable-adjusted Cox regression showed that urinary exosomal bkv-miR-B1-5p levels at 2 weeks and 3 months posttransplant independently predicted biopsy-proven BKVN development. In particular, the early increase in urinary exosomal bkv-miR-B1-5p makes its predictive ability for biopsy-proven BKVN superior to that of plasma BKV DNA at 2 weeks posttransplant.

Conclusion

Our results suggest that urinary exosomal bkv-miR-B1-5p can be used to identify the KRTs at high risk for BKVN at earlier time than plasma BKV DNA loads, enabling earlier intervention.